1st and only VMAT2 inhibitor approved for both TD and HD chorea1

AUS-45561

COMING SOON

ONCE-DAILY DOSING with EXTENDED-RELEASE FORMULATION

Move forward with

HD, Huntington’s disease; TD, tardive dyskinesia; VMAT2, vesicular monoamine transporter 2.

REFERENCE: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.